Nuvilex, Inc.'s Dr. Gerald Crabtree Discusses Upcoming Phase III Cancer Trials, Fast Track and Orphan Drug Status

Nuvilex, Inc.'s Dr. Gerald Crabtree Discusses Upcoming Phase III Cancer Trials, 
Fast Track and Orphan Drug Status 
NEW YORK, NY -- (Marketwired) -- 05/13/13 --  Nuvilex, Inc. (OTCQB:
NVLX) COO Dr. Gerald Crabtree is no stranger to late stage clinical
trials or dealing with blockbuster therapies for cancer patients.
It's likely that is exactly why he is the COO at the small Silver
Spring, Maryland, biotech. The road that Nuvilex is currently on --
preparing for a large scale Phase III clinical trial to treat
advanced, inoperable pancreatic cancer using its cell encapsulation
technology combined with the cancer killing drug, ifosfamide -- Dr.
Crabtree is no stranger to traveling.  
With a great deal of excitement surrounding this company's technology
and the amazing results it's shown in clinical trials against
advanced pancreatic cancer and in pre-clinical studies in diabetes
and against mammary tumors, there are many new investors taking a
look at the company. Some are new to biotechnology stocks and some
are new to the Phase III clinical trials process, so as you can
imagine, this is generating plenty of questions surrounding what
Nuvilex must endure to begin those trials.  
Stock House Group, a research and content development investor
relations firm, spoke extensively about the company's upcoming trials
with Dr. Crabtree who has had a large role in several Phase III
trials including a role with the team at Bristol-Myers Squibb that
developed the blockbuster cancer drug, Taxol. In our discussion, Dr.
Crabtree addressed some of the items that must be dealt with before a
late-stage clinical trial can begin, the study sites, seeking "orphan
drug" and "fast track" status and where Nuvilex is in the process. 
Read our full interview with Dr. Gerald Crabtree to learn what plans
Nuvilex, Inc. has for their upcoming Phase III clinical trials to
treat advanced, inoperable pancreatic cancer at 
About Stock House Group
 Stock House Group is a full service
Investment Relations firm specializing in Awareness, Research, and
Content Development. The firm offers a platform that allows CEOs to
tell their story through the press with Feature Articles, Research
Reports, and CEO Interviews. At the same time, Stock House Group is
building a library of Research for Investors to use that allows them
to get more informed on small cap stocks. For more information visit
Stock House Group at  
Stock House Group
(646) 397-4020 
Press spacebar to pause and continue. Press esc to stop.